Pages that link to "Q83562183"
Jump to navigation
Jump to search
The following pages link to KCNJ11 gene E23K variant and therapeutic response to sulfonylureas (Q83562183):
Displaying 35 items.
- Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents (Q26751138) (← links)
- KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus (Q28085471) (← links)
- Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery (Q28274686) (← links)
- Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs (Q30248914) (← links)
- Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? (Q30388214) (← links)
- Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data (Q30571118) (← links)
- KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment. (Q33771570) (← links)
- Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. (Q33790423) (← links)
- Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo population (Q33858377) (← links)
- Patient profiling in diabetes and role of canagliflozin (Q34729268) (← links)
- An analysis of the association between a polymorphism of KCNJ11 and diabetic retinopathy in a Chinese Han population (Q34993310) (← links)
- Monogenic Diabetes: What It Teaches Us on the Common Forms of Type 1 and Type 2 Diabetes (Q36960085) (← links)
- Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes (Q37134345) (← links)
- Pharmacogenetics of oral antidiabetic drugs. (Q37353476) (← links)
- Pharmacogenetics and personalized treatment of type 2 diabetes (Q37508445) (← links)
- Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes (Q37571899) (← links)
- Genetic variants in KCNJ11, TCF7L2 and HNF4A are associated with type 2 diabetes, BMI and dyslipidemia in families of Northeastern Mexico: A pilot study. (Q37697725) (← links)
- The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs (Q38110432) (← links)
- Genetics of drug response in type 2 diabetes (Q38480670) (← links)
- Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation (Q38711541) (← links)
- Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? (Q38747416) (← links)
- The Application of Genomics in Diabetes: Barriers to Discovery and Implementation (Q39123582) (← links)
- Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide (Q41505625) (← links)
- Association between E23K variant in KCNJ11 gene and new-onset diabetes after liver transplantation (Q42208034) (← links)
- Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. (Q45869049) (← links)
- CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients (Q51328309) (← links)
- Pharmacogenetics of Sulfonylureas (Q57918700) (← links)
- Frequency of (, and ) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin (Q64075045) (← links)
- Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine (Q90267161) (← links)
- Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel (Q92508730) (← links)
- The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico (Q94544622) (← links)
- Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care (Q96172065) (← links)
- Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank (Q98156851) (← links)
- Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes (Q99545741) (← links)
- Pharmacogenetics of Type 2 Diabetes-Progress and Prospects (Q99605020) (← links)